Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1995 2
1996 1
1998 2
2000 1
2001 2
2003 3
2004 3
2005 9
2006 4
2007 2
2008 5
2009 10
2010 9
2011 14
2012 15
2013 13
2014 16
2015 28
2016 18
2017 20
2018 22
2019 20
2020 22
2021 20
2022 9
2023 10
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

248 results

Results by year

Filters applied: . Clear all
Page 1
Renal dysplasia.
Chen RY, Chang H. Chen RY, et al. Arch Pathol Lab Med. 2015 Apr;139(4):547-51. doi: 10.5858/arpa.2013-0660-RS. Arch Pathol Lab Med. 2015. PMID: 25822765 Free article. Review.
Immunohistochemical expression of the paired box genes 2 and 8 (PAX2/8) and Wilms tumor 1 (WT1) is increased in the primitive ducts and fibromuscular collar, respectively. ...
Immunohistochemical expression of the paired box genes 2 and 8 (PAX2/8) and Wilms tumor 1 (WT1) is increased in the pri …
Wilms' tumor 1 gene in hematopoietic malignancies: clinical implications and future directions.
Luo P, Jing W, Yi K, Wu S, Zhou F. Luo P, et al. Leuk Lymphoma. 2020 Sep;61(9):2059-2067. doi: 10.1080/10428194.2020.1762884. Epub 2020 May 13. Leuk Lymphoma. 2020. PMID: 32401109 Review.
The Wilms' tumor 1 (WT1) gene is an important regulatory molecule that plays a vital role in cell growth and development. ...
The Wilms' tumor 1 (WT1) gene is an important regulatory molecule that plays a vital role in cell growth and developmen …
Comprehensive Genomic Profiling of NF2-Mutated Kidney Tumors Reveals Potential Targets for Therapy.
Hacking SM, Pavlick D, Wang Y, Carneiro BA, Mullally M, Lu S, Canepa M, Bratslavsky G, Jacob J, Necchi A, Spiess PE, Wang L, Yakirevich E, Ross J. Hacking SM, et al. Oncologist. 2023 Jul 5;28(7):e508-e519. doi: 10.1093/oncolo/oyad040. Oncologist. 2023. PMID: 36917021 Free PMC article.
NF2 GA frequency was highest in cdRCC (30%), sRCC (21%), uRCC (15%), and pRCC (12%) while lowest in ccRCC (3%), UC (3%) Wilms tumor (1%), and chRCC (0%). NF2 mutational status was associated with loss of Ch 22 (P < .001). ...
NF2 GA frequency was highest in cdRCC (30%), sRCC (21%), uRCC (15%), and pRCC (12%) while lowest in ccRCC (3%), UC (3%) Wilms tumo …
Wilms Tumor 1 Expression at Diagnosis Correlates With Genetic Abnormalities and Polymorphism But Is Not Independently Prognostic in Acute Myelogenous Leukemia: A Hokkaido Leukemia Net Study.
Hidaka D, Onozawa M, Hashiguchi J, Miyashita N, Kasahara K, Fujisawa S, Hayase E, Okada K, Shiratori S, Goto H, Sugita J, Nakagawa M, Hashimoto D, Kahata K, Endo T, Yamamoto S, Tsutsumi Y, Haseyama Y, Nagashima T, Mori A, Ota S, Sakai H, Ishihara T, Imai K, Miyagishima T, Kakinoki Y, Kurosawa M, Kobayashi H, Iwasaki H, Shimizu C, Kondo T, Teshima T. Hidaka D, et al. Clin Lymphoma Myeloma Leuk. 2018 Nov;18(11):e469-e479. doi: 10.1016/j.clml.2018.07.291. Epub 2018 Jul 17. Clin Lymphoma Myeloma Leuk. 2018. PMID: 30082223 Free article.
BACKGROUND: The prognostic effect of Wilms tumor 1 (WT1) expression at the diagnosis of acute myelogenous leukemia (AML) has been controversial. ...
BACKGROUND: The prognostic effect of Wilms tumor 1 (WT1) expression at the diagnosis of acute myelogenous leukemia (AML …
Wilms' tumor 1 (WT1) expression and prognosis in solid cancer patients: a systematic review and meta-analysis.
Qi XW, Zhang F, Wu H, Liu JL, Zong BG, Xu C, Jiang J. Qi XW, et al. Sci Rep. 2015 Mar 9;5:8924. doi: 10.1038/srep08924. Sci Rep. 2015. PMID: 25748047 Free PMC article. Review.
Though proposed as a promising target antigen for cancer immunotherapy, the prognostic value of Wilms' tumor 1 (WT1) in solid tumors remains inconclusive. Here, we report a systematic review and meta-analysis of the association between WT1 expression and prog …
Though proposed as a promising target antigen for cancer immunotherapy, the prognostic value of Wilms' tumor 1 (WT1) in …
Role of cancer immunology in chronic myelogenous leukemia.
Ureshino H, Shindo T, Kimura S. Ureshino H, et al. Leuk Res. 2020 Jan;88:106273. doi: 10.1016/j.leukres.2019.106273. Epub 2019 Nov 18. Leuk Res. 2020. PMID: 31765938 Review.
Although regulation mechanism of these immune system has not been fully elucidated, tumor antigen (e.g. Wilms tumor-1), and surface receptors (e.g. killer immunoglobulin-like receptor and natural killer group 2) on NK cells, are pivotal role in these immune s …
Although regulation mechanism of these immune system has not been fully elucidated, tumor antigen (e.g. Wilms tumor-1), …
Wilms tumor 1 (WT1) protein: Diagnostic utility in pediatric tumors.
Salvatorelli L, Parenti R, Leone G, Musumeci G, Vasquez E, Magro G. Salvatorelli L, et al. Acta Histochem. 2015 May-Jun;117(4-5):367-78. doi: 10.1016/j.acthis.2015.03.010. Epub 2015 Apr 14. Acta Histochem. 2015. PMID: 25881478 Review.
Despite Wilms tumor 1 (WT1) protein was originally considered as a specific immunomarker of Wilms tumor, with the increasing use of immunohistochemistry, there is evidence that other tumors may share WT1 protein expression. ...
Despite Wilms tumor 1 (WT1) protein was originally considered as a specific immunomarker of Wilms tumor, with the incre …
Evaluation of glomerular sirtuin-1 and claudin-1 in the pathophysiology of nondiabetic focal segmental glomerulosclerosis.
Lopes-Gonçalves G, Costa-Pessoa JM, Pimenta R, Tostes AF, da Silva EM, Ledesma FL, Malheiros DMAC, Zatz R, Thieme K, Câmara NOS, Oliveira-Souza M. Lopes-Gonçalves G, et al. Sci Rep. 2023 Dec 19;13(1):22685. doi: 10.1038/s41598-023-49861-0. Sci Rep. 2023. PMID: 38114708 Free PMC article.
From this, we investigated whether a small molecule activator of SIRT1, SRT1720, could delay the onset of FSGS in an animal model of adriamycin (ADR)-induced nephropathy; 14 days of treatment with SRT1720 attenuated glomerulosclerosis progression and albuminuria, prevented transc …
From this, we investigated whether a small molecule activator of SIRT1, SRT1720, could delay the onset of FSGS in an animal model of adriamy …
Ancillary studies in pleural, pericardial, and peritoneal effusion cytology.
Sundling KE, Cibas ES. Sundling KE, et al. Cancer Cytopathol. 2018 Aug;126 Suppl 8:590-598. doi: 10.1002/cncy.22021. Cancer Cytopathol. 2018. PMID: 30156768 Free article. Review.
The differentiation of reactive mesothelial cells from malignant mesothelioma and adenocarcinoma is a recurring theme, and Wilms tumor 1 (WT1)/AE1/AE3, claudin 4, and BRCA1-associated protein 1 (BAP1) immunostains are useful new tools in the armamentarium. .. …
The differentiation of reactive mesothelial cells from malignant mesothelioma and adenocarcinoma is a recurring theme, and Wilms t …
Wilms' tumor 1 antigen immunoreactivity in epithelial ovarian cancer - diagnostic and prognostic value.
Zarychta E, Lepinay K, Szubert S, Jozwicki J, Misiak J, Brozyna AA, Kosinska-Kaczynska K, Lewandowska A, Malicka E, Makarewicz A, Rhone P, Jozwicki W. Zarychta E, et al. Folia Histochem Cytobiol. 2020;58(3):198-207. doi: 10.5603/FHC.a2020.0022. Epub 2020 Sep 22. Folia Histochem Cytobiol. 2020. PMID: 32960974 Free article.
OBJECTIVES: Ovarian cancer is a heterogeneous disease, with a number of different histological subtypes with various responses to treatment. Wilms' tumor 1 (WT1) immunoreactivity is used to distinguish between OC's various subtypes. ...
OBJECTIVES: Ovarian cancer is a heterogeneous disease, with a number of different histological subtypes with various responses to treatment. …
248 results